公开(公告)号：US20250017867A1

公开(公告)日：2025-01-16

申请号：US18695076

申请日：2022-09-30

Applicant: ModernaTX, Inc.

Inventor： Michael Albert Zimmer ,  Xinhua Yan ,  Mihir Metkar ,  David Reid

IPC: A61K9/51 ,  A61K9/127 ,  A61K31/7105 ,  A61K38/22

Abstract: This disclosure relates to mRNA therapy for the treatment of relaxin-related diseases, disorders or conditions such as, e.g., fibrosis or cardiovascular disease (e.g., acute heart failure or acute coronary syndrome). mRNAs for use in the invention, when administered in vivo, encode relaxin. mRNA therapies of the disclosure increase and/or restore deficient levels of relaxin expression and/or activity in subjects.